BIOVENTUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.98 USD | -2.21% |
|
-11.16% | -24.48% |
| 03-13 | Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating | MT |
| 03-12 | Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company has insufficient levels of profitability.
- The company is in debt and has limited leeway for investment
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -24.48% | 254M | C | ||
| +73.17% | 12.38B | B- | ||
| -18.74% | 7.92B | C+ | ||
| +16.15% | 7.2B | C- | ||
| +4.81% | 5.84B | B | ||
| +5.99% | 5.01B | D+ | ||
| +27.07% | 4.53B | - | ||
| -21.67% | 3.88B | B- | ||
| -40.82% | 2.23B | C | ||
| +1.49% | 2.02B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BVS Stock
- Ratings Bioventus Inc.
